IDEXX Laboratories, Inc. (NASDAQ:IDXX) Position Lowered by Greenleaf Trust

Greenleaf Trust trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,631 shares of the company’s stock after selling 35 shares during the period. Greenleaf Trust’s holdings in IDEXX Laboratories were worth $905,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Panagora Asset Management Inc. increased its holdings in shares of IDEXX Laboratories by 50.3% in the 1st quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock valued at $1,768,000 after acquiring an additional 1,081 shares during the last quarter. Raymond James Trust N.A. increased its stake in IDEXX Laboratories by 26.8% during the first quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock valued at $888,000 after purchasing an additional 343 shares during the last quarter. Cetera Investment Advisers raised its holdings in shares of IDEXX Laboratories by 77.1% during the first quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock worth $2,010,000 after purchasing an additional 1,600 shares during the period. Moors & Cabot Inc. raised its holdings in shares of IDEXX Laboratories by 3.0% during the first quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock worth $961,000 after purchasing an additional 52 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in shares of IDEXX Laboratories by 15.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock worth $543,000 after buying an additional 134 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.3 %

NASDAQ:IDXX opened at $476.35 on Monday. The stock has a market cap of $39.56 billion, a price-to-earnings ratio of 47.30, a PEG ratio of 3.67 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The business has a fifty day moving average of $538.02 and a 200-day moving average of $509.93.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. During the same quarter in the prior year, the firm posted $2.05 EPS. IDEXX Laboratories’s revenue was up 8.8% compared to the same quarter last year. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on IDXX. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research report on Tuesday, January 30th. The Goldman Sachs Group raised their price target on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Barclays raised their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

Insider Activity

In related news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock worth $24,871,960 over the last three months. Corporate insiders own 2.18% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.